Sanad M H, Sallam Kh M, Marzook F A, Abd-Elhaliem S M
Labeled Compounds Department, Radioisotopes Production and Radioactive Sources Division, Hot Laboratories Center, Atomic Energy Authority, P.O. Box 13759, Cairo, Egypt.
J Labelled Comp Radiopharm. 2016 Oct;59(12):484-491. doi: 10.1002/jlcr.3435. Epub 2016 Sep 16.
The goal of the study aims to evaluate newly radioiodinated candesartan (CAN) as a potential cardiovascular tracer. CAN was labeled using I with chloramine-T (Ch-T) and N-bromosuccinimide (NBS) with full characterization of cold Iodo-candesartan. Factors such as pH, reaction temperature, reaction time, substrate, and oxidizing agent amounts were studied to optimize the radioiodination of CAN. The optimum radiochemical yield of I-CAN was 98%. The labeled compound was separated and purified using high-pressure liquid chromatography. The biological distribution indicates the suitability of I-CAN as a novel tracer to detect cardiovascular disorders.
本研究的目的旨在评估新的放射性碘化坎地沙坦（CAN）作为一种潜在的心血管示踪剂。使用氯胺-T（Ch-T）和N-溴代琥珀酰亚胺（NBS）对CAN进行碘标记，并对冷碘代坎地沙坦进行全面表征。研究了pH值、反应温度、反应时间、底物和氧化剂用量等因素，以优化CAN的放射性碘化。I-CAN的最佳放射化学产率为98%。使用高压液相色谱法对标记化合物进行分离和纯化。生物分布表明I-CAN作为一种新型示踪剂可用于检测心血管疾病。
